Plain-English translation of NCT06635330 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing Anti-CD19 CAR-T cell therapy, a type of cancer immunotherapy for children with relapsed or refractory B-cell acute lymphoblastic leukemia (a blood cancer that hasn't responded to standard chemotherapy). The treatment works by taking your child's own immune cells, modifying them in a laboratory to recognize and fight leukemia cells, and then giving them back to your child. Researchers want to see if this treatment is safe and effective for children whose leukemia has come back or stopped responding to other treatments.
Children whose leukemia returns or doesn't respond to standard chemotherapy have very few treatment options and face poor outcomes. This trial exists to see whether this newer immunotherapy approach can offer hope to children in this difficult situation.
You likely qualify if…
You likely don't qualify if…
Your child will undergo apheresis to collect immune cells from their blood. These cells will be sent to a laboratory where they are genetically modified to recognize and attack leukemia cells. Once ready, the modified cells will be given back to your child through an infusion. Your child will need follow-up visits to monitor safety and how well the treatment is working. The trial will track your child's health closely over time to assess both side effects and whether the leukemia responds to the treatment.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Iran